Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers

Yardena Samuels, Zhenghe Wang, Alberto Bardelli et al. · Science · 2004 · 3.4K citations

Medicine, Genetics, Oncology +11

<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

Astrid Lièvre, Jean‐Baptiste Bachet, Delphine Le Corre et al. · Cancer Research · 2006 · 2.2K citations

Medicine, Oncology, Pharmacology +17

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

Ingo K. Mellinghoff, Maria Y. Wang, Igor Vivanco et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text

Medicine, Molecular Medicine, Oncology +16

Somatic activation of the K-ras oncogene causes early onset lung cancer in mice

Leisa Johnson, Kim L. Mercer, Doron C. Greenbaum et al. · Nature · 2001 · 1.2K citations

Medicine, Molecular Genetics, Oncology +14

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13